Danielle M. Brander, MD, Duke Cancer Institute
Advertisement
Articles by Danielle M. Brander, MD, Duke Cancer Institute
Advertisement
Latest Updated Articles
Therapeutic Sequencing in Relapsed/Refractory CLLJanuary 8th 2021
Allogeneic Transplantation for CLLJanuary 8th 2021
Frontline CLL Treatment: Addressing Unmet NeedsJanuary 8th 2021
Selecting Frontline Therapy to Treat CLLJanuary 8th 2021
Frontline CLL Treatment With Fixed-Duration RegimensJanuary 8th 2021
Minimal Residual Disease in CLLJanuary 8th 2021
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5